Results of a cytomegalovirus (CMV)-specific CD8 +/interferon- γ + cytokine flow cytometry assay correlate with clinical evidence of protective immunity in patients with AIDS with CMV retinitis

Mark A. Jacobson, Holden T. Maecker, Patricia L. Orr, Ron D'Amico, Mark L Van Natta, Xiao Dong Li, Richard B. Pollard, Barry M. Bredt

Research output: Contribution to journalArticle

Abstract

To evaluate the potential clinical utility of a cytomegalovirus (CMV)-specific CD8 +/interferon (IFN)-γ + cytokine flow cytometry (CFC) assay for patients with CMV retinitis (CMVR), stored peripheral blood mononuclear cell specimens were obtained from patients with active CMVR (i.e., having clinical evidence of absent CMV-protective immunity), as well as from highly active antiretroviral therapy-treated patients with CMVR who were able to discontinue anti-CMV therapy without subsequent progression of retinitis (i.e., having clinical evidence of restored CMV-protective immunity). Positive CD8 +/IFN-γ + T lymphocyte responses to CMV phosphoprotein 65 or immediate early peptide-pool stimulation were present in specimens from only 3 of 10 patients with active CMVR but were present in at least 1 specimen from all 20 patients with immunorestored CMVR, with a mean of 2.4 specimens/patient tested, spanning up to 6 months of observation (P = .0001). Among the patients with immunorestored CMVR, positive responses were present in all longitudinal specimens from 15 of the 20 patients. These data suggest that further testing of the CMV-specific CD8 +/IFN- γ + CFC assay, for clinical utility in predicting incident and progressive CMVR disease, is warranted.

Original languageEnglish (US)
Pages (from-to)1362-1373
Number of pages12
JournalJournal of Infectious Diseases
Volume189
Issue number8
DOIs
StatePublished - Apr 15 2004

Fingerprint

Cytomegalovirus Retinitis
Retinitis
Cytomegalovirus
Interferons
Immunity
Flow Cytometry
Acquired Immunodeficiency Syndrome
Cytokines
CD8-Positive T-Lymphocytes
Highly Active Antiretroviral Therapy
Blood Cells
Observation
Peptides

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Results of a cytomegalovirus (CMV)-specific CD8 +/interferon- γ + cytokine flow cytometry assay correlate with clinical evidence of protective immunity in patients with AIDS with CMV retinitis. / Jacobson, Mark A.; Maecker, Holden T.; Orr, Patricia L.; D'Amico, Ron; Van Natta, Mark L; Li, Xiao Dong; Pollard, Richard B.; Bredt, Barry M.

In: Journal of Infectious Diseases, Vol. 189, No. 8, 15.04.2004, p. 1362-1373.

Research output: Contribution to journalArticle

Jacobson, Mark A. ; Maecker, Holden T. ; Orr, Patricia L. ; D'Amico, Ron ; Van Natta, Mark L ; Li, Xiao Dong ; Pollard, Richard B. ; Bredt, Barry M. / Results of a cytomegalovirus (CMV)-specific CD8 +/interferon- γ + cytokine flow cytometry assay correlate with clinical evidence of protective immunity in patients with AIDS with CMV retinitis. In: Journal of Infectious Diseases. 2004 ; Vol. 189, No. 8. pp. 1362-1373.
@article{df2b34f49a6e4e3ebf36358059530ce3,
title = "Results of a cytomegalovirus (CMV)-specific CD8 +/interferon- γ + cytokine flow cytometry assay correlate with clinical evidence of protective immunity in patients with AIDS with CMV retinitis",
abstract = "To evaluate the potential clinical utility of a cytomegalovirus (CMV)-specific CD8 +/interferon (IFN)-γ + cytokine flow cytometry (CFC) assay for patients with CMV retinitis (CMVR), stored peripheral blood mononuclear cell specimens were obtained from patients with active CMVR (i.e., having clinical evidence of absent CMV-protective immunity), as well as from highly active antiretroviral therapy-treated patients with CMVR who were able to discontinue anti-CMV therapy without subsequent progression of retinitis (i.e., having clinical evidence of restored CMV-protective immunity). Positive CD8 +/IFN-γ + T lymphocyte responses to CMV phosphoprotein 65 or immediate early peptide-pool stimulation were present in specimens from only 3 of 10 patients with active CMVR but were present in at least 1 specimen from all 20 patients with immunorestored CMVR, with a mean of 2.4 specimens/patient tested, spanning up to 6 months of observation (P = .0001). Among the patients with immunorestored CMVR, positive responses were present in all longitudinal specimens from 15 of the 20 patients. These data suggest that further testing of the CMV-specific CD8 +/IFN- γ + CFC assay, for clinical utility in predicting incident and progressive CMVR disease, is warranted.",
author = "Jacobson, {Mark A.} and Maecker, {Holden T.} and Orr, {Patricia L.} and Ron D'Amico and {Van Natta}, {Mark L} and Li, {Xiao Dong} and Pollard, {Richard B.} and Bredt, {Barry M.}",
year = "2004",
month = "4",
day = "15",
doi = "10.1086/382964",
language = "English (US)",
volume = "189",
pages = "1362--1373",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Results of a cytomegalovirus (CMV)-specific CD8 +/interferon- γ + cytokine flow cytometry assay correlate with clinical evidence of protective immunity in patients with AIDS with CMV retinitis

AU - Jacobson, Mark A.

AU - Maecker, Holden T.

AU - Orr, Patricia L.

AU - D'Amico, Ron

AU - Van Natta, Mark L

AU - Li, Xiao Dong

AU - Pollard, Richard B.

AU - Bredt, Barry M.

PY - 2004/4/15

Y1 - 2004/4/15

N2 - To evaluate the potential clinical utility of a cytomegalovirus (CMV)-specific CD8 +/interferon (IFN)-γ + cytokine flow cytometry (CFC) assay for patients with CMV retinitis (CMVR), stored peripheral blood mononuclear cell specimens were obtained from patients with active CMVR (i.e., having clinical evidence of absent CMV-protective immunity), as well as from highly active antiretroviral therapy-treated patients with CMVR who were able to discontinue anti-CMV therapy without subsequent progression of retinitis (i.e., having clinical evidence of restored CMV-protective immunity). Positive CD8 +/IFN-γ + T lymphocyte responses to CMV phosphoprotein 65 or immediate early peptide-pool stimulation were present in specimens from only 3 of 10 patients with active CMVR but were present in at least 1 specimen from all 20 patients with immunorestored CMVR, with a mean of 2.4 specimens/patient tested, spanning up to 6 months of observation (P = .0001). Among the patients with immunorestored CMVR, positive responses were present in all longitudinal specimens from 15 of the 20 patients. These data suggest that further testing of the CMV-specific CD8 +/IFN- γ + CFC assay, for clinical utility in predicting incident and progressive CMVR disease, is warranted.

AB - To evaluate the potential clinical utility of a cytomegalovirus (CMV)-specific CD8 +/interferon (IFN)-γ + cytokine flow cytometry (CFC) assay for patients with CMV retinitis (CMVR), stored peripheral blood mononuclear cell specimens were obtained from patients with active CMVR (i.e., having clinical evidence of absent CMV-protective immunity), as well as from highly active antiretroviral therapy-treated patients with CMVR who were able to discontinue anti-CMV therapy without subsequent progression of retinitis (i.e., having clinical evidence of restored CMV-protective immunity). Positive CD8 +/IFN-γ + T lymphocyte responses to CMV phosphoprotein 65 or immediate early peptide-pool stimulation were present in specimens from only 3 of 10 patients with active CMVR but were present in at least 1 specimen from all 20 patients with immunorestored CMVR, with a mean of 2.4 specimens/patient tested, spanning up to 6 months of observation (P = .0001). Among the patients with immunorestored CMVR, positive responses were present in all longitudinal specimens from 15 of the 20 patients. These data suggest that further testing of the CMV-specific CD8 +/IFN- γ + CFC assay, for clinical utility in predicting incident and progressive CMVR disease, is warranted.

UR - http://www.scopus.com/inward/record.url?scp=2142820858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2142820858&partnerID=8YFLogxK

U2 - 10.1086/382964

DO - 10.1086/382964

M3 - Article

C2 - 15073672

AN - SCOPUS:2142820858

VL - 189

SP - 1362

EP - 1373

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 8

ER -